On the 14th, G2GBIO showed a strong rise of over 50% in the early trading session. Kyobo 18th Special Purpose Acquisition Company (SPAC), which debuted alongside G2GBIO, is experiencing fluctuations in the 10-20% range.
As of 9:06 a.m. that day, G2GBIO was trading at 88,800 won, which is an increase of 30,800 won (53.10%) compared to the reference price of 58,000 won. Kyobo 18th SPAC was up 160 won (8%) to 2,160 won compared to its reference price of 2,000 won.
G2GBIO is a corporation with a long-acting injectable platform based on membrane emulsification, called "InnoLAMP." It is a technology that creates uniform particles by passing an organic solution containing polymers and drugs through a membrane at a certain pressure. This technology is used for impurity removal, increasing drug content, and enhancing the bioavailability of drugs.
G2GBIO has signed a long-acting injectable development contract with Boehringer Ingelheim and is also known to have signed joint development agreements with two other global pharmaceutical companies.
Kyobo 18th SPAC is a special purpose corporation established for the purpose of mergers and acquisitions. The sectors targeted for mergers include renewable energy, biopharmaceuticals, medical devices, IT convergence systems, carbon reduction energy, and LED applications, among 13 others.